Cargando…

Preclinical pharmacokinetics of benznidazole.

Benznidazole is a lipophilic analogue of misonidazole (MISO) which shows promise as a chemosensitizer for clinical use, particularly in combination with CCNU. We have investigated the detailed pharmacokinetics of benznidazole in mice, dogs and sheep to provide a data base for the estimation of doses...

Descripción completa

Detalles Bibliográficos
Autores principales:	Workman, P., White, R. A., Walton, M. I., Owen, L. N., Twentyman, P. R.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1984
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1976805/ https://www.ncbi.nlm.nih.gov/pubmed/6466543

Ejemplares similares

Benznidazole
por: Soares-Sobrinho, José Lamartine, et al.
Publicado: (2008)

Population pharmacokinetic modeling of benznidazole in Brazilian patients with chronic Chagas disease
por: Frade, Virgínia Paula, et al.
Publicado: (2022)

Optical Absorption of the Antitrypanocidal Drug Benznidazole in Water
por: Bezerra, Eveline M., et al.
Publicado: (2014)

The role of dexamethasone in the modification of misonidazole pharmacokinetics.
por: Jones, D. H., et al.
Publicado: (1983)

Population pharmacokinetics of benznidazole in neonates, infants and children using a new pediatric formulation
por: Altcheh, Jaime, et al.
Publicado: (2023)

Effects of localised tumour hyperthermia on pimonidazole (Ro 03-8799) pharmacokinetics in mice.
por: Walton, M. I., et al.
Publicado: (1989)

Drug transporter and oxidative stress gene expression in human macrophages infected with benznidazole-sensitive and naturally benznidazole-resistant Trypanosoma cruzi parasites treated with benznidazole
por: Téllez, Jair, et al.
Publicado: (2019)

The effects of whole body hyperthermia on the pharmacokinetics and toxicity of the basic 2-nitroimidazole radiosensitizer Ro 03-8799 in mice.
por: Walton, M. I., et al.
Publicado: (1987)

Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026
por: Nutley, B P, et al.
Publicado: (2005)

An investigation of the possibility of chemosensitization by clinically achievable concentrations of misonidazole.
por: Twentyman, P. R., et al.
Publicado: (1983)

Structure/activity relationships for the enhancement by electron-affinic drugs of the anti-tumour effect of CCNU.
por: Workman, P., et al.
Publicado: (1982)

Chemosensitization by lipophilic nitroimidazoles.
por: Twentyman, P. R., et al.
Publicado: (1983)

Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole
por: Fernández, Marisa Liliana, et al.
Publicado: (2016)

Effect of misonidazole or metronidazole pretreatment on the response of the RIF-1 mouse sarcoma to melphalan, cyclophosphamide, chlorambucil and CCNU.
por: Twentyman, P., et al.
Publicado: (1982)

Benznidazole Biotransformation and Multiple Targets in Trypanosoma cruzi Revealed by Metabolomics
por: Trochine, Andrea, et al.
Publicado: (2014)

Population Pharmacokinetic Study of Benznidazole in Pediatric Chagas Disease Suggests Efficacy despite Lower Plasma Concentrations than in Adults
por: Altcheh, Jaime, et al.
Publicado: (2014)

Retention of activity by selected anthracyclines in a multidrug resistant human large cell lung carcinoma line without P-glycoprotein hyperexpression.
por: Coley, H. M., et al.
Publicado: (1991)

The effects of alpha and gamma interferons on human lung cancer cells grown in vitro or as xenografts in nude mice.
por: Twentyman, P. R., et al.
Publicado: (1985)

Pharmacokinetic and tumour-penetration properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-9963) in dogs
por: White, R. A. S., et al.
Publicado: (1980)

Nanocarrier-enhanced intracellular delivery of benznidazole for treatment of Trypanosoma cruzi infection
por: Li, Xiaomo, et al.
Publicado: (2021)

Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
por: Rolon, Miriam, et al.
Publicado: (2022)

Molecular characterization of the hexose transporter gene in benznidazole resistant and susceptible populations of Trypanosoma cruzi
por: dos Santos, Paula F, et al.
Publicado: (2012)

Hepatic changes by benznidazole in a specific treatment for Chagas disease
por: Pavan, Tycha Bianca Sabaini, et al.
Publicado: (2018)

Benznidazole Treatment of Chagasic Encephalitis in Pregnant Woman with AIDS
por: Bisio, Margarita, et al.
Publicado: (2013)

Transcriptomic analysis of benznidazole-resistant and susceptible Trypanosoma cruzi populations
por: Lima, Davi Alvarenga, et al.
Publicado: (2023)

Access to Chagas disease treatment in the United States after the regulatory approval of benznidazole
por: Yoshioka, Kota, et al.
Publicado: (2020)

Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice.
por: Workman, P.
Publicado: (1979)

Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas’ disease
por: Jackson, Yves, et al.
Publicado: (2020)

Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease
por: Rial, Marcela S., et al.
Publicado: (2017)

Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines.
por: Coley, H. M., et al.
Publicado: (1993)

Access to benznidazole for Chagas disease in the United States—Cautious optimism?
por: Alpern, Jonathan D., et al.
Publicado: (2017)

Combined Treatment of Heterocyclic Analogues and Benznidazole upon Trypanosoma cruzi In Vivo
por: Batista, Denise da Gama Jaén, et al.
Publicado: (2011)

Genotoxicity Revaluation of Three Commercial Nitroheterocyclic Drugs: Nifurtimox, Benznidazole, and Metronidazole
por: Buschini, Annamaria, et al.
Publicado: (2009)

The fecal, oral, and skin microbiota of children with Chagas disease treated with benznidazole
por: Robello, Carlos, et al.
Publicado: (2019)

Beneficial effects of benznidazole in Chagas disease: NIH SaMi-Trop cohort study
por: Cardoso, Clareci Silva, et al.
Publicado: (2018)

Tolerance and Adherence of Patients with Chronic Chagas Disease Treated with Benznidazole
por: Vázquez, Cristina, et al.
Publicado: (2023)

Nanostructured lipid carriers containing benznidazole: physicochemical, biopharmaceutical and cellular in vitro studies
por: Muraca, Giuliana, et al.
Publicado: (2023)

Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277.
por: Foster, B. J., et al.
Publicado: (1993)

Dried Blood Spot Technique-Based Liquid Chromatography-Tandem Mass Spectrometry Method as a Simple Alternative for Benznidazole Pharmacokinetic Assessment
por: Galindo Bedor, Danilo César, et al.
Publicado: (2018)

Benznidazole and Posaconazole in Experimental Chagas Disease: Positive Interaction in Concomitant and Sequential Treatments
por: Diniz, Lívia de Figueiredo, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_rf6ntlar407m8hft17aebsf57i